Chevy Chase Clinical Research
Clinical Trials
Chevy Chase Clinical Research is the largest program of its kind in the region. Founded in 1996 as part of Affiliated Research Centers, it now operates as an independent research site in partnership with Capital Digestive Care. Over 300 studies have been conducted, covering a wide range of gastroenterology and select areas of internal medicine. Below is a summary of our active clinical trials.
Current Clinical Trials
If you are interested in participating in a clinical trial please contact our office at research@capitaldigestivecare.com or (301) 652-5520.
Clostridium Difficile
This study is for patients 18 years of age or older who currently test positive for Clostridium difficile, better known as C. Diff. The study is 27-weeks, which is designed to evaluate the safety, tolerability, and efficacy of study medication in reduction of recurrence of C-difficile Infection (CDI) in Adults who have received antibacterial drug treatment for recurrent CDI. There is also an additional 27-week extension option for this protocol.
Diabetic Gastroparesis
This study is for patients 18 years of age or older who have been diagnosed with Diabetic Gastroparesis.There is also a continuation and long-term extension study option for this protocol.
Crohn’s Disease
We have multiple studies for Crohn’s diseasefor patients between the ages of 18-75 years old. The potential patient needs to have moderate to severe symptoms with active disease. Due to the many study options that we offer, the patient can either be biologic naïve OR needs to have failed traditional therapy (i.e. 6-Mp, Steroids, TNF-Inhibitors, etc.). The patient must be willing to undergo a colonoscopy as a study requirement. Clinical trial medications include oral agents, sub-cutaneous injectables, IV infusions, and more.
Ulcerative Colitis
We have multiple studies for ulcerative colitisfor patients between the ages of 18-75 years old. The potential patient needs to have moderate to severe symptoms with active disease. Due to the many study options that we offer, the patient can either be currently receiving treatment with Infliximab OR has loss of response to at least 1 conventional treatment (i.e. mesalamine, glucocorticoids, immunosuppressants, 6-mercaptopurine, methotrexate, anti-TNF, etc). Clinical trial medications include oral agents, sub-cutaneous injectables, IV infusions, and more.
